Rajnath Singh to release first batch of DRDO’s 2DG medicine for treating COVID-19 patients today

Published by
WEB DESK

New Delhi: The first batch of the 2-deoxy-D-glucose (2-DG) drug developed by the Defence Research and Development Organisation (DRDO) for treatment of Covid-19 will be released by Defence Minister Rajnath Singh on Monday.

Rajnath Singh’s office tweeted,”Raksha Mantri Rajnath Singh will release the first batch of anti-Covid drug 2DG via video conferencing facility tomorrow at 10.30 AM. The drug has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy’s Laboratories.”

The first batch of 10,000 doses of 2DG medicine would be launched early next week, informed Defence Research and Development Organisation officials to ANI on Friday.

The official informed, “The first batch of 10,000 doses of 2DG medicine for the treatment of COVID-19 infected patients would be launched early next week and will be given to patients.”

“The drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr Anant Narayan Bhatt”, informed DRDO officials.

“An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad”, informed an official release by Ministry of Defence.
Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.

Share
Leave a Comment